Corboz M R, Ballard S T, Inglis S K, Taylor A E
College of Medicine, University of South Alabama, Mobile 36688, USA.
Am J Respir Crit Care Med. 1996 Mar;153(3):1093-7. doi: 10.1164/ajrccm.153.3.8630550.
Previous study of adrenergic control of the tracheal vasculature in rats (1) demonstrated that beta-adrenergic blockade heightened arteriolar and large venular contractile responses to norepinephrine, a nonselective alpha-adrenergic agonist. The present study was undertaken to confirm the presence of functional beta-adrenergic receptors and to determine which beta-adrenergic receptor subtypes mediate vasodilation in this tissue. Tracheal adventitial arterioles (12.0 to 47.0 micro m initial diameter, n=39) and venules (48.0 to 98.5 micrometers initial diameter, n=44) were observed through a video microscope, and vessel diameters were measured. Vessels were preconstricted with 10(-4) M phenylephrine (PHE), a selective alpha 1-adrenergic agonist, to achieve sufficient tone for measurement of dilation responses. When vessels were treated only with PHE, arterioles and venules constricted to 55.9% and 67.6% of their initial diameter, respectively, after 15 min of suffusion. When preconstricted vessels were treated with the nonselective beta-adrenergic agonist isoproterenol (10(-5) M), both arterioles and venules significantly dilated from 63.4% to 82.9% and from 71.5% to 81.3% of their initial diameters. At high concentration (10(-5) M), the putative beta 2-adrenergic agonist terbutaline also caused preconstricted arterioles and venules to significantly dilate from 70.8% to 79.8% and from 71.5% to 83.4% of their initial diameters. The selective beta 1-adrenergic antagonist atenolol (10(-6) M) did not affect terbutaline-induced dilation in preconstricted arterioles, but greatly attenuated dilation in preconstricted venules. From these data, we conclude that beta 2-adrenergic receptors are present in and mediate dilation of tracheal arterioles, and also, that the dilation in large tracheal venules is mediated in large part through beta 1-adrenergic receptors.
先前对大鼠气管血管系统肾上腺素能控制的研究(1)表明,β-肾上腺素能阻断增强了小动脉和大静脉对去甲肾上腺素(一种非选择性α-肾上腺素能激动剂)的收缩反应。本研究旨在确认功能性β-肾上腺素能受体的存在,并确定哪种β-肾上腺素能受体亚型介导该组织中的血管舒张。通过视频显微镜观察气管外膜小动脉(初始直径12.0至47.0微米,n = 39)和小静脉(初始直径48.0至98.5微米,n = 44),并测量血管直径。用10⁻⁴M去氧肾上腺素(PHE,一种选择性α1-肾上腺素能激动剂)预收缩血管,以获得足够的张力来测量舒张反应。当血管仅用PHE处理时,灌注15分钟后,小动脉和小静脉分别收缩至其初始直径的55.9%和67.6%。当用非选择性β-肾上腺素能激动剂异丙肾上腺素(10⁻⁵M)处理预收缩的血管时,小动脉和小静脉均从其初始直径的63.4%显著舒张至82.9%,从71.5%显著舒张至81.3%。在高浓度(10⁻⁵M)时,假定的β2-肾上腺素能激动剂特布他林也使预收缩的小动脉和小静脉从其初始直径的70.8%显著舒张至79.8%,从71.5%显著舒张至83.4%。选择性β1-肾上腺素能拮抗剂阿替洛尔(10⁻⁶M)不影响特布他林诱导的预收缩小动脉的舒张,但大大减弱了预收缩小静脉的舒张。根据这些数据,我们得出结论,β2-肾上腺素能受体存在于气管小动脉中并介导其舒张,并且,大气管小静脉的舒张在很大程度上是通过β1-肾上腺素能受体介导的。